Antitussive properties of inhaled bronchodilators on induced cough.
We have studied the antitussive effects of two anticholinergic agents, oxitropium bromide (200 micrograms) and ipratropium bromide (80 micrograms), and a combined beta-agonist and anticholinergic preparation containing fenoterol hydrobromide (200 micrograms) and ipratropium bromide (80 micrograms), in 16 normal and ten asthmatic volunteers in a double-blind, randomized, placebo-controlled crossover trial. Cough was induced by inhalation of ultrasonically nebulized distilled water and hypotonic saline solution. All treatments significantly reduced the cough response to inhaled distilled water aerosol when compared with placebo (p less than 0.001). There was no difference between oxitropium bromide and ipratropium bromide (p greater than 0.05), but the combination preparation displayed a greater antitussive effect than either oxitropium bromide (p less than 0.05) or ipratropium bromide (p less than 0.025). Cough frequencies in response to hypotonic 0.18 and 0.32 percent saline aerosol were lower than those obtained with distilled water (p less than 0.005) for all treatments. Asthmatic patients coughed less frequently than normal volunteers in response to all solutions when placebo was given (p less than 0.05), but there is no evidence to suggest that the response to treatment was different in the two groups. Our results suggest that inhaled anticholinergic bronchodilators alone or in combination with beta 2-adrenergic agonists might be effective in the treatment of pathologic cough.
Lowry
R
R
Department of Respiratory Physiology, Addenbrooke's Hospital, Cambridge, England.
Wood
A
A
Johnson
T
T
Higenbottam
T
T
D000280:Administration, Inhalation; D000328:Adult; D001249:Asthma / Q000188:drug therapy*; D001286:Atropine Derivatives / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D003371:Cough / Q000139:chemically induced / Q000188:drug therapy*; D004311:Double-Blind Method; D004338:Drug Combinations / Q000627:therapeutic use; D004341:Drug Evaluation; D004357:Drug Synergism; D005260:Female; D005280:Fenoterol / Q000627:therapeutic use*; D006801:Humans; D009241:Ipratropium / Q000627:therapeutic use*; D008297:Male; D008448:Maximal Expiratory Flow Rate; D011897:Random Allocation; D012602:Scopolamine Derivatives / Q000627:therapeutic use*
D001286:Atropine Derivatives; D001993:Bronchodilator Agents; D004338:Drug Combinations; D012602:Scopolamine Derivatives; C030809:fenoterol, ipratropium drug combination; D005280:Fenoterol; C017590:oxitropium; D009241:Ipratropium